BLAZE-1

AbCellera-Discovered Antibody Granted Interim Authorization by Health Canada as a Treatment for COVID-19

Retrieved on: 
Friday, November 20, 2020
FDA, Health, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Life sciences, Health sciences, Biotechnology, Pharmaceutical industry, Draft:Bamlanivimab, AbCellera, Emergency Use Authorization, Eua, Food and Drug Administration, Biopharmaceutical, Bamlanivimab, BLAZE-1, AbCellera Biologics Inc.

Details regarding the interim authorization can be found here .

Key Points: 
  • Details regarding the interim authorization can be found here .
  • Bamlanivimab received emergency use authorization (EUA) from the U.S. Food and Drug Administration on November 9, 2020.
  • Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19.
  • AbCellera's partners include leading biotechnology companies, global health organizations, and many of the top 10 biopharmaceutical companies.

 AbCellera-Discovered Antibody Receives U.S. FDA Emergency Use Authorization as a Monotherapy for the Treatment of COVID-19

Retrieved on: 
Tuesday, November 10, 2020
Research, Infectious diseases, FDA, Clinical trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Medical specialties, Medicine, Clinical medicine, Immunology, Draft:Bamlanivimab, Immune system, Glycoproteins, Antibodies, Biotechnology, Neutralizing antibody, Coronavirus disease, Monoclonal antibody, bamlanivimab, BLAZE-1, AbCellera Biologics Inc.

We commend the Lilly team for their tireless efforts to combat COVID-19 and for starting antibody manufacturing at risk in advance of clinical results.

Key Points: 
  • We commend the Lilly team for their tireless efforts to combat COVID-19 and for starting antibody manufacturing at risk in advance of clinical results.
  • Bamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2.
  • It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19.
  • Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19.